On May 17th, 2023, Mercer Global Advisors Inc. ADV announced that it had raised its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by an impressive 10.3% during the fourth quarter of 2022. The move saw the firm acquire an additional 12,356 shares in the pharmaceutical giant, bringing its total ownership to a staggering 131,766 shares.
The news marks yet another significant investment made by Mercer Global Advisors Inc. ADV in healthcare firms and reaffirms the company’s confidence in Takeda Pharmaceutical Company Limited as a top-performing player in the market.
With holdings worth $2,056,000 as of its most recent filing with the Securities and Exchange Commission (SEC), it is clear that Mercer Global Advisors Inc. ADV sees significant potential for growth within Takeda Pharmaceutical Company Limited.
Investors who are interested in learning more about hedge funds holding TAK can visit HoldingsChannel.com for up-to-date information on their latest 13F filings and insider trades.
As of May 17th, NYSE TAK opened at $16.45 per share with a market cap of $52.06 billion. The company boasts an attractive price-to-earnings ratio of just 21.36 and has a beta of only 0.63 – a reflection of its low volatility compared to other stocks on the exchange.
Despite moderate market volatility over recent months, there is reason to believe that Takeda Pharmaceutical Company Limited is well positioned for future growth. With a healthy current ratio of 0.97 and quick ratio of 0.57, combined with manageable debt levels represented by a debt-to-equity ratio of just 0.64, investors should take note that this company could be poised for profitable gains over the longer term.
In short, while investing always carries some degree of risk regardless of industry or sector, given current trends and growth forecasts, Takeda Pharmaceutical Company Limited represents a compelling opportunity in the evolving world of healthcare.
[bs_forecast_slider ticker=”TAK”]
Takeda Pharmaceutical Co, Ltd. Attracts Institutional Investor Attention and Positive Ratings from Brokerages
Takeda Pharmaceutical Co, Ltd. has garnered significant attention from institutional investors as of late, with various large investors increasing their stakes in the company during the first quarter of this year. For instance, Raymond James & Associates grew its stake by 28.2% during this time while Bank of Montreal Can increased its position by 29.6%. American Century Companies Inc. and Bank of New York Mellon Corp also saw notable growth in their holdings, increasing their positions by 14.5% and 26.1%, respectively.
These moves by institutional investors come amid positive ratings from brokerages such as Bank of America, which upgraded Takeda Pharmaceutical to a “buy” rating and set a price target of $20 for the company earlier this year. Another brokerage that has been bullish on Takeda recently is TD Cowen, which increased its target price on the pharmaceutical firm’s stock from $24 to $30 and provided an “outperform” rating in a research report issued on April 4th.
Overall, Bloomberg.com indicates that Takeda Pharmaceutical currently has an average rating of “Moderate Buy” among analysts who cover the company, with a median price target of $24.67.
As for what exactly Takeda Pharmaceutical does, the corporation engages in various pharmaceutical-related activities such as research and development, manufacture, import/export sales, and marketing of drugs across three primary segments: Prescription Drugs, Consumer Healthcare, and Other.
As these recent investments and positive ratings suggest, it seems that there is growing interest in Takeda Pharmaceutical among institutional investors due to its strong performance within the pharmaceutical industry as well as its potential for future growth. Only time will tell how this momentum continues to build over time but so far it appears that many believe Takeda Pharmaceutical could be poised for success going forward.
